Le Lézard
Classified in: Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Photo/Multimedia, Conference Call, Webcast

Nutanix Reports First Quarter Fiscal 2021 Financial Results


Nutanix, Inc. (NASDAQ: NTNX), a leader in private cloud, hybrid, and multicloud computing, today announced financial results for its first quarter ended October 31, 2020.

"We are pleased with our financial performance in the first quarter, which marked a strong start to fiscal 2021 including increased adoption of new products as well as continued growth in our core hyperconverged infrastructure software," said Dheeraj Pandey, Chairman, Co-Founder and CEO of Nutanix. "After launching our solutions on AWS in August, we announced a major partnership with Microsoft to develop our portfolio on Azure, placing the Nutanix HCI (Hybrid Cloud Infrastructure) at a significant competitive advantage to help our customers build out their hybrid and multicloud environments."

"Our ACV-first strategy and solid go-to-market execution drove outperformance across all key financial metrics including ACV billings growth of 10 percent year-over-year and run-rate ACV growth of 29 percent year-over-year," said Duston Williams, CFO of Nutanix. "Looking ahead, we remain focused on thoughtfully managing operating expenses as we continue to execute on our business model transformation and are confident in Nutanix's ability to drive long-term growth for the benefit of all stakeholders."

First Quarter Fiscal 2021 Financial Summary

 

Q1 FY'21

Q1 FY'20

Y/Y Change

Annual Contract Value (ACV)1 Billings

$137.8 million

 

$125.6 million

 

10%

Run-rate Annual Contract Value (ACV)2

$1.29 billion

 

$1.00 billion

 

29%

Total Average Contract Term3

3.5 years

 

3.9 years

 

(0.4) years

Total Revenue4

$312.8 million

 

$314.8 million

 

(0.6)%

GAAP Gross Margin

78.3%

 

77.1%

 

120 bps

Non-GAAP Gross Margin

81.9%

 

80.1%

 

180 bps

GAAP Operating Expenses

$426.9 million

 

$462.9 million

 

(8)%

Non-GAAP Operating Expenses

$341.2 million

 

$386.3 million

 

(12)%

Free Cash Flow

$(16.3) million

 

$(44.4) million

 

$28 million

Reconciliations between GAAP and non-GAAP financial measures and key performance measures are provided in the tables of this press release.

Recent Company Highlights

Second Quarter Fiscal 2021 Outlook

 

Q2 FY'21 Outlook

ACV Billings

$145-$148 million

Non-GAAP Gross Margin

Approximately 81.5%

Non-GAAP Operating Expenses

$360-$370 million

Weighted Shares Outstanding

Approximately 202 million

Supplementary materials to this press release, including our first quarter fiscal year 2021 earnings presentation, can be found at https://ir.nutanix.com/company/financial.

Webcast and Conference Call Information

Nutanix executives will discuss the company's first quarter fiscal 2021 financial results on a conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time. To listen to the call via telephone, dial 1-833-227-5841 from within the United States or 1-647-689-4068 from outside the United States. The conference ID is 3994985. This call will be webcast live and available to all interested parties on our Investor Relations website at ir.nutanix.com. Shortly after the conclusion of the conference call, a replay of the audio webcast will be available on our Investor Relations website. A telephonic replay will be available for one week and can be accessed by calling 1-800-585-8367 or 1-416-621-4642, and entering the conference ID 3994985.

Definitions and Total Revenue Impact

1Annual Contract Value, or ACV, is defined as the total annualized value of a contract, excluding amounts related to professional services and hardware. The total annualized value for a contract is calculated by dividing the total value of the contract by the number of years in the term of such contract, using, where applicable, an assumed term of five years for contracts that do not have a specified term. ACV Billings for any given period is defined as the sum of the ACV for all contracts billed during the given period.

2Run-rate ACV at the end of any period, is the sum of ACV for all contracts that are in effect as of the end of that period. For the purposes of this calculation, the company assumes that the contract term begins on the date a contract is booked, irrespective of the periods in which we would recognize revenue for such contract.

3Total Average Contract Term represents the dollar-weighted term, calculated on a billings basis, across all subscription and life-of-device contracts, using an assumed term of five years for life-of-device licenses, executed in the quarter.

4Total Revenue was negatively impacted by year-over-year decline in average contract term associated with the ongoing transition to a subscription-based business model.

Non-GAAP Financial Measures and Other Key Performance Measures

To supplement our consolidated financial statements, which are prepared and presented in accordance with GAAP, we use the following non-GAAP financial and other key performance measures: billings, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP net loss, non-GAAP net loss per share, free cash flow, subscription revenue, subscription billings, Annual Contract Value billings (or ACV billings), Run-rate Annual Contract Value (or Run-rate ACV), and professional services billings. In computing these non-GAAP financial measures and key performance measures, we exclude certain items such as stock-based compensation and the related income tax impact, costs associated with our acquisitions (such as amortization of acquired intangible assets, income tax-related impact, and other acquisition-related costs), impairment of operating lease-related assets, change in fair value of derivative liability, amortization of debt discount and issuance costs, non-cash interest expense, other non-recurring transactions and the related tax impact, and the revenue and billings associated with pass-through hardware sales. Billings is a performance measure which we believe provides useful information to investors because it represents the amounts under binding purchase orders received by us during a given period that have been billed, and we calculate billings by adding the change in deferred revenue between the start and end of the period to total revenue recognized in the same period. Non-GAAP gross margin, non-GAAP operating expenses, non-GAAP net loss, and non-GAAP net loss per share are financial measures which we believe provide useful information to investors because they provide meaningful supplemental information regarding our performance and liquidity by excluding certain expenses and expenditures such as stock-based compensation expense that may not be indicative of our ongoing core business operating results. Free cash flow is a performance measure that we believe provides useful information to our management and investors about the amount of cash generated by the business after necessary capital expenditures, and we define free cash flow as net cash used in operating activities less purchases of property and equipment. Subscription revenue, subscription billings, and professional services billings are performance measures that we believe provide useful information to our management and investors as they allow us to better track the growth of the subscription-based portion of our business, which is a critical part of our business plan. ACV billings and Run-rate ACV are performance measures that we believe provide useful information to our management and investors as they allow us to better track the topline growth of our business during our transition to a subscription-based business model because they take into account variability in term lengths. We use these non-GAAP financial and key performance measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. However, these non-GAAP financial and key performance measures have limitations as analytical tools and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP. Billings, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP net loss, non-GAAP net loss per share, and free cash flow are not substitutes for total revenue, gross margin, operating expenses, net loss, net loss per share, or net cash (used in) provided by operating activities, respectively; subscription revenue is not a substitute for total revenue; and subscription and professional services billings are not substitutes for subscription and professional services revenue, respectively. There is no GAAP measure that is comparable to either ACV billings or Run-rate ACV, so we have not reconciled either ACV billings or Run-rate ACV numbers included in this press release to any GAAP measure. In addition, other companies, including companies in our industry, may calculate non-GAAP financial measures and key performance measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures and key performance measures as tools for comparison. We urge you to review the reconciliation of our non-GAAP financial measures and key performance measures to the most directly comparable GAAP financial measures included below in the tables captioned "Reconciliation of Revenue to Billings," "Disaggregation of Revenue and Billings," "Reconciliation of Subscription and Professional Services Revenue to Subscription and Professional Services Billings," "Reconciliation of GAAP to Non-GAAP Profit Measures," and "Reconciliation of GAAP Net Cash Used In Operating Activities to Non-GAAP Free Cash Flow," and not to rely on any single financial measure to evaluate our business.

Forward-Looking Statements

This press release contains express and implied forward-looking statements, including, but not limited to, statements regarding: our business plans, initiatives, objectives and outlook, including changes we have made or anticipate making in response to the COVID-19 pandemic and the launch of our new global partner program, our ability to manage our business during the pandemic, and the position we anticipate being in following the pandemic; our ability to execute such plans, initiatives and objectives successfully and in a timely manner, and the benefits and impact of such plans, initiatives and objectives, including our ability to manage our expenses and decrease our cash usage in future periods and drive long-term growth; the competitive market, including our competitive position, our projections about our market share and the size of our total addressable market; our customer needs and our response to those needs; the benefits and capabilities of our platform, solutions, products, services and technology, including the interoperability and availability of our solutions with and on third-party platforms; our plans and expectations regarding new products, services, product features and technology, including those that are still under development or in process; the success and impact of our customer, partner, industry, analyst, investor, and employee events on our business, including on future pipeline generation; our plans and timing for, and the success and impact of, our transition to a subscription-based business model and our changes in guidance metrics; the timing and potential impact of the COVID-19 pandemic on the global market environment and the IT industry, as well as on our business, operations and financial results, including the actions we have taken to manage operating expenses; and our guidance on estimated ACV Billings, non-GAAP gross margin, non-GAAP operating expenses and weighted shares outstanding for any future fiscal periods. These forward-looking statements are not historical facts and instead are based on our current expectations, estimates, opinions, and beliefs. Consequently, you should not rely on these forward-looking statements. The accuracy of these forward-looking statements depends upon future events and involves risks, uncertainties, and other factors, including factors that may be beyond our control, that may cause these statements to be inaccurate and cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by such statements, including, among others: failure to successfully implement or realize the full benefits of, or unexpected difficulties or delays in successfully implementing or realizing the full benefits of, our business plans, initiatives and objectives; the timing, breadth, and impact of the COVID-19 pandemic on our business, operations, and financial results, as well as the impact on our customers, partners, and end markets; failure to timely and successfully meet our customer needs; delays in or lack of customer or market acceptance of our new products, services, product features or technology; delays or unexpected accelerations in the transition to a subscription-based business model; the rapid evolution of the markets in which we compete; our ability to achieve, sustain and/or manage future growth effectively; factors that could result in the significant fluctuation of our future quarterly operating results, including, among other things, anticipated changes to our revenue and product mix, including changes as a result of our transition to a subscription-based business model, which will slow revenue growth during such transition and make forecasting future performance more difficult, the timing and magnitude of orders, shipments and acceptance of our solutions in any given quarter, our ability to attract new and retain existing end-customers, changes in the pricing of certain components of our solutions, and fluctuations in demand and competitive pricing pressures for our solutions; the introduction, or acceleration of adoption of, competing solutions, including public cloud infrastructure; and other risks detailed in our Annual Report on Form 10-K for the fiscal year ended July 31, 2020, filed with the U.S. Securities and Exchange Commission, or the SEC, on September 23, 2020. Additional information will also be set forth in our Quarterly Report on Form 10-Q that will be filed for the fiscal quarter ended October 31, 2020 which should be read in conjunction with this press release and the financial results included herein. Our SEC filings are available on the Investor Relations section of the company's website at ir.nutanix.com and on the SEC's website at www.sec.gov. These forward-looking statements speak only as of the date of this press release and, except as required by law, we assume no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any of these forward-looking statements to reflect actual results or subsequent events or circumstances.

About Nutanix

Nutanix is a global leader in cloud software and a pioneer in hyperconverged infrastructure solutions, making computing invisible anywhere. Organizations around the world use Nutanix software to leverage a single platform to manage any app at any location for their private, hybrid and multicloud environments. Learn more at www.nutanix.com or follow us on Twitter @nutanix.

© 2020 Nutanix, Inc. All rights reserved. Nutanix, the Nutanix logo, and all Nutanix product and service names mentioned herein are registered trademarks or trademarks of Nutanix, Inc. in the United States and other countries. All other brand names mentioned herein are for identification purposes only and may be the trademarks of their respective holder(s). This press release contains links to external websites that are not part of Nutanix.com. Nutanix does not control these sites and disclaims all responsibility for the content or accuracy of any external site. Our decision to link to an external site should not be considered an endorsement of any content on such a site.

NUTANIX, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

 

As of

 

July 31,
2020

October 31,
2020

 

 

 

 

(in thousands)

Assets

 

 

Current assets:

 

 

Cash and cash equivalents

$

318,737

 

$

504,482

 

Short-term investments

 

401,041

 

 

813,603

 

Accounts receivable, net

 

242,516

 

 

183,270

 

Deferred commissions?current

 

68,694

 

 

76,047

 

Prepaid expenses and other current assets

 

63,032

 

 

56,719

 

Total current assets

 

1,094,020

 

 

1,634,121

 

Property and equipment, net

 

143,172

 

 

133,156

 

Operating lease right-of-use assets

 

127,326

 

 

126,542

 

Deferred commissions?non-current

 

146,834

 

 

167,711

 

Intangible assets, net

 

49,392

 

 

45,047

 

Goodwill

 

185,260

 

 

185,260

 

Other assets?non-current

 

22,543

 

 

24,035

 

Total assets

$

1,768,547

 

$

2,315,872

 

 

 

 

Liabilities and Stockholders' Deficit

 

 

Current liabilities:

 

 

Accounts payable

$

54,029

 

$

48,272

 

Accrued compensation and benefits

 

109,109

 

 

115,725

 

Accrued expenses and other current liabilities

 

25,924

 

 

24,563

 

Deferred revenue?current

 

534,572

 

 

549,938

 

Operating lease liabilities?current

 

36,569

 

 

41,080

 

Total current liabilities

 

760,203

 

 

779,578

 

Deferred revenue?non-current

 

648,869

 

 

656,545

 

Operating lease liabilities?non-current

 

116,794

 

 

113,491

 

Convertible senior notes, net

 

490,222

 

 

994,637

 

Derivative liability

 

?

 

 

295,650

 

Other liabilities?non-current

 

27,436

 

 

33,326

 

Total liabilities

 

2,043,524

 

 

2,873,227

 

Stockholders' deficit:

 

 

Common stock

 

5

 

 

5

 

Additional paid-in capital

 

2,245,180

 

 

2,299,903

 

Accumulated other comprehensive income

 

2,030

 

 

880

 

Accumulated deficit

 

(2,522,192

)

 

(2,858,143

)

Total stockholders' deficit

 

(274,977

)

 

(557,355

)

Total liabilities and stockholders' deficit

$

1,768,547

 

$

2,315,872

 

NUTANIX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

Three Months Ended
October 31,

 

2019

2020

 

 

 

 

(in thousands, except per share data)

Revenue:

 

 

Product

$

192,444

 

$

155,752

 

Support, entitlements and other services

 

122,324

 

 

157,002

 

Total revenue

 

314,768

 

 

312,754

 

Cost of revenue:

 

 

Product (1)(2)

 

21,233

 

 

12,814

 

Support, entitlements and other services (1)

 

50,968

 

 

55,145

 

Total cost of revenue

 

72,201

 

 

67,959

 

Gross profit

 

242,567

 

 

244,795

 

Operating expenses:

 

 

Sales and marketing (1)(2)

 

291,838

 

 

257,290

 

Research and development (1)

 

138,206

 

 

135,804

 

General and administrative (1)

 

32,860

 

 

33,774

 

Total operating expenses

 

462,904

 

 

426,868

 

Loss from operations

 

(220,337

)

 

(182,073

)

Other expense, net

 

(5,040

)

 

(78,732

)

Loss before provision for income taxes

 

(225,377

)

 

(260,805

)

Provision for income taxes

 

3,923

 

 

4,243

 

Net loss

$

(229,300

)

$

(265,048

)

Net loss per share attributable to Class A and Class B common stockholders?basic and diluted

$

(1.21

)

$

(1.31

)

Weighted average shares used in computing net loss per share attributable to Class A and Class B common stockholders?basic and diluted

 

189,671

 

 

203,095

 

__________________________________________________

(1)

Includes the following stock-based compensation expense:

 

Three Months Ended
October 31,

 

2019

2020

 

 

 

 

(in thousands)

Product cost of revenue

$

1,112

 

$

1,504

 

Support, entitlements and other services cost of revenue

 

4,751

 

5,761

Sales and marketing

 

27,775

 

 

32,227

 

Research and development

 

37,563

 

 

37,887

 

General and administrative

 

10,225

 

 

11,819

 

Total stock-based compensation expense

$

81,426

 

$

89,198

 

(2)

Includes the following amortization of intangible assets:

 

Three Months Ended
October 31,

 

2019

2020

 

 

 

 

(in thousands)

Product cost of revenue

$

3,694

 

$

3,694

 

Sales and marketing

 

651

 

651

Total amortization of intangible assets

$

4,345

 

$

4,345

 

NUTANIX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

Three Months Ended
October 31,

 

2019

2020

 

 

 

 

(in thousands)

Cash flows from operating activities:

 

 

Net loss

$

(229,300

)

$

(265,048

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

Depreciation and amortization

 

22,462

 

 

23,499

 

Stock-based compensation

 

81,426

 

 

89,198

 

Change in fair value of derivative liability

 

?

 

 

64,740

 

Amortization of debt discount and debt issuance costs

 

7,635

 

 

11,708

 

Operating lease cost, net of accretion

 

6,671

 

 

8,347

 

Impairment of lease-related assets

 

?

 

 

2,822

 

Non-cash interest expense

 

?

 

 

1,952

 

Other

 

103

 

 

1,671

 

Changes in operating assets and liabilities:

 

 

Accounts receivable, net

 

30,592

 

 

60,094

 

Deferred commissions

 

(18,313

)

 

(28,230

)

Prepaid expenses and other assets

 

16,150

 

 

6,222

 

Accounts payable

 

5,208

 

 

(4,075

)

Accrued compensation and benefits

 

(4,786

)

 

10,041

 

Accrued expenses and other liabilities

 

(5,772

)

 

(1,238

)

Operating leases, net

 

(3,469

)

 

(7,970

)

Deferred revenue

 

65,230

 

 

22,194

 

Net cash used in operating activities

 

(26,163

)

 

(4,073

)

Cash flows from investing activities:

 

 

Maturities of investments

 

171,441

 

 

97,578

 

Purchases of investments

 

(321,474

)

 

(513,998

)

Sales of investments

 

7,870

 

 

?

 

Purchases of property and equipment

 

(18,203

)

 

(12,252

)

Net cash used in investing activities

 

(160,366

)

 

(428,672

)

Cash flows from financing activities:

 

 

Proceeds from sales of shares through employee equity incentive plans

 

23,973

 

 

19,600

 

Proceeds from the issuance of convertible notes, net of issuance costs

 

?

 

 

723,757

 

Repurchases of common stock

 

?

 

 

(125,079

)

Net cash provided by financing activities

 

23,973

 

 

618,278

 

Net (decrease) increase in cash, cash equivalents and restricted cash

$

(162,556

)

$

185,533

 

Cash, cash equivalents and restricted cash?beginning of period

 

399,520

 

 

321,991

 

Cash, cash equivalents and restricted cash?end of period

$

236,964

 

$

507,524

 

Restricted cash (1)

 

3,144

 

 

3,042

 

Cash and cash equivalents?end of period

$

233,820

 

$

504,482

 

Supplemental disclosures of cash flow information:

 

 

Cash paid for income taxes

$

7,779

 

$

5,050

 

Supplemental disclosures of non-cash investing and financing information:

 

 

Purchases of property and equipment included in accounts payable and accrued liabilities

$

12,200

 

$

2,948

 

__________________________________________________

(1)

Included within other assets?non-current in the condensed consolidated balance sheets.

Reconciliation of Revenue to Billings

(Unaudited)

 

Three Months Ended
October 31,

 

2019

2020

 

 

 

 

(in thousands)

Total revenue

$

314,768

 

$

312,754

 

Change in deferred revenue

 

65,230

 

 

22,194

 

Total billings

$

379,998

 

$

334,948

 

Disaggregation of Revenue and Billings

(Unaudited)

 

 

Three Months Ended
October 31,

 

2019

2020

 

 

 

 

(in thousands)

Disaggregation of Revenue:

 

 

Subscription

$

217,896

 

$

278,165

 

Non-portable software

 

77,571

 

 

20,043

 

Hardware

 

9,724

 

 

729

 

Professional services

 

9,577

 

 

13,817

 

Total revenue

$

314,768

 

$

312,754

 

 

 

 

Disaggregation of Billings:

 

 

Subscription

$

275,538

 

$

293,923

 

Non-portable software

 

77,571

 

 

20,043

 

Hardware

 

9,724

 

 

729

 

Professional services

 

17,165

 

 

20,253

 

Total billings

$

379,998

 

$

334,948

 

Subscription ? Subscription revenue includes any performance obligation which has a defined term, and is generated from the sales of software entitlement and support subscriptions, subscription software licenses and cloud-based Software as a Service, or SaaS offerings.

Non-portable software ? Non-portable software revenue includes sales of our enterprise cloud platform when delivered on a configured-to-order appliance by us or one of our OEM partners. The software licenses associated with these sales are typically non-portable and have a term equal to the life of the appliance on which the software is delivered. Revenue from our non-portable software products is generally recognized upon transfer of control to the customer.

Hardware ? In transactions where we deliver the hardware appliance, we consider ourselves to be the principal in the transaction and we record revenue and costs of goods sold on a gross basis. We consider the amount allocated to hardware revenue to be equivalent to the cost of the hardware procured. Hardware revenue is generally recognized upon transfer of control to the customer.

Professional services ? We also sell professional services with our products. We recognize revenue related to professional services as they are performed.

Annual Contract Value Billings and Run-rate Annual Contract Value

(Unaudited)

 

 

Three Months Ended
October 31,

 

2019

2020

 

 

 

 

(in thousands)

Annual Contract Value Billings (ACV Billings)

$

125,575

$

137,831

 

Run-rate Annual Contract Value (Run-rate ACV)

$

1,002,117

 

$

1,290,742

 

Reconciliation of Subscription and Professional Services Revenue to Subscription and Professional Services Billings

(Unaudited)

 

 

Three Months Ended
October 31,

 

2019

2020

 

 

 

 

(in thousands)

Subscription revenue

$

217,896

 

 

$

278,165

 

Change in subscription deferred revenue

 

57,642

 

 

15,758

Subscription billings

$

275,538

 

 

$

293,923

 

 

 

 

 

Professional services revenue

$

9,577

 

 

$

13,817

 

Change in professional services deferred revenue

 

7,588

 

 

 

6,436

 

Professional services billings

$

17,165

 

 

$

20,253

 

Reconciliation of GAAP to Non-GAAP Profit Measures

(Unaudited)

 

 

GAAP

Non-GAAP Adjustments

Non-GAAP

 

Three Months Ended October 31, 2020

(1)

 

(2)

 

(3)

 

(4)

 

(5)

 

(6)

 

(7)

Three Months Ended October 31, 2020

 

 

 

 

 

 

 

 

 

 

 

(in thousands, except percentages and per share data)

Gross profit

$

244,795

 

$

7,265

 

$

3,694

 

$

287

 

$

?

 

$

?

$

?

$

?

$

256,041

 

Gross margin

 

78.3

%

 

2.3

%

 

1.2

%

 

0.1

%

 

?

 

 

?

 

 

?

 

 

?

 

 

81.9

%

Operating expenses:

 

 

 

 

 

 

 

 

 

Sales and marketing

 

257,290

 

 

(32,227

)

 

(651

)

 

?

 

 

?

 

 

?

 

 

?

 

 

?

 

 

224,412

 

Research and development

 

135,804

 

 

(37,887

)

 

?

 

 

(2,535

)

 

?

 

 

?

 

 

?

 

 

?

 

 

95,382

 

General and administrative

 

33,774

 

 

(11,819

)

 

?

 

 

?

 

 

(506

)

 

?

 

 

?

 

 

?

 

 

21,449

 

Total operating expenses

 

426,868

 

 

(81,933

)

 

(651

)

 

(2,535

)

 

(506

)

 

?

 

 

?

 

 

?

 

 

341,243

 

Loss from operations

 

(182,073

)

 

89,198

 

 

4,345

 

 

2,822

 

 

506

 

 

?

 

 

?

 

 

?

 

 

(85,202

)

Net loss

$

(265,048

)

$

89,198

 

$

4,345

 

$

2,822

 

$

506

 

$

64,740

 

$

13,660

 

$

393

 

$

(89,384

)

Weighted shares outstanding, basic and diluted

 

203,095

 

 

 

 

 

 

 

 

 

203,095

 

Net loss per share, basic and diluted

$

(1.31

)

$

0.44

 

$

0.02

 

$

0.02

 

$

?

 

$

0.32

 

$

0.07

 

$

?

 

$

(0.44

)

__________________________________________________

(1)

Stock-based compensation

(2)

Amortization of intangible assets

(3)

Impairment of lease-related assets

(4)

Other

(5)

Change in fair value of derivative liability

(6)

Amortization of debt discount and issuance costs and non-cash interest expense

(7)

Income tax effect primarily related to stock-based compensation expense

 

GAAP

Non-GAAP Adjustments

Non-GAAP

 

Three Months Ended October 31, 2019

(1)

 

(2)

 

(3)

 

(4)

 

(5)

Three Months Ended October 31, 2019

 

 

 

 

 

 

 

 

 

(in thousands, except percentages and per share data)

Gross profit

$

242,567

 

$

5,863

 

$

3,694

 

$

?

 

$

?

$

?

$

252,124

 

Gross margin

 

77.1

%

 

1.8

%

 

1.2

%

 

?

 

 

?

 

 

?

 

 

80.1

%

Operating expenses:

 

 

 

 

 

 

 

Sales and marketing

 

291,838

 

 

(27,775

)

 

(651

)

 

?

 

 

?

 

 

?

 

 

263,412

 

Research and development

 

138,206

 

 

(37,563

)

 

?

 

 

?

 

 

?

 

 

?

 

 

100,643

 

General and administrative

 

32,860

 

 

(10,225

)

 

?

 

 

(353

)

 

?

 

 

?

 

 

22,282

 

Total operating expenses

 

462,904

 

 

(75,563

)

 

(651

)

 

(353

)

 

?

 

 

?

 

 

386,337

 

Loss from operations

 

(220,337

)

 

81,426

 

 

4,345

 

 

353

 

 

?

 

 

?

 

 

(134,213

)

Net loss

$

(229,300

)

$

81,426

 

$

4,345

 

$

353

 

$

7,635

 

$

213

 

$

(135,328

)

Weighted shares outstanding, basic and diluted

 

189,671

 

 

 

 

 

 

 

189,671

 

Net loss per share, basic and diluted

$

(1.21

)

$

0.43

 

$

0.03

 

$

?

 

$

0.04

 

$

?

 

$

(0.71

)

__________________________________________________

(1)

Stock-based compensation

(2)

Amortization of intangible assets

(3)

Other

(4)

Amortization of debt discount and debt issuance costs

(5)

Income tax effect primarily related to stock-based compensation expense

Reconciliation of GAAP Net Cash Used In Operating Activities to Non-GAAP Free Cash Flow

(Unaudited)

 

Three Months Ended
October 31,

 

2019

2020

 

 

 

 

(in thousands)

Net cash used in operating activities

$

(26,163

)

$

(4,073

)

Purchases of property and equipment

 

(18,203

)

 

(12,252

)

Free cash flow

$

(44,366

)

$

(16,325

)

 


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
Discovery Silver Corp. ("Discovery" or the "Company") today announced financial results for the three and twelve months ended December 31, 2023 ("Q4 2023" and "2023", respectively). The Company also provided a summary of key events since the...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...

28 mar 2024
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Will all...

28 mar 2024
Boat Rocker Media Inc. ("Boat Rocker" or the "Company") , an independent, integrated global entertainment company, today reported its financial results for the three months ended December 31, 2023 ("fourth quarter" or "Q4") and for the year ended...



News published on and distributed by: